Advertisement

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement

Jan

21

Today In Oncology

Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma

Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer

Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy

Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer

Advertisement

© 2021 HSP News Service, L.L.C.